The 3rd Obesity & Weight Loss Drug Development Summit stands out as the premier gathering for leaders in obesity therapeutic development from novel targets, to preclinical, translational, and clinical development. Unlike other events, it uniquely combines cutting-edge science with practical insights on navigating the evolving regulatory landscape and implementing personalized medicine strategies. This summit attracts the highest-level experts in obesity drug development from leading pharmaceutical and biotech companies, including the big-players in the field, Novo Nordisk, Eli Lilly and Boehringer Ingelheim, offering unparalleled networking opportunities and access to 70+ of the most influential voices shaping the future of this critical field.
Partners
What is the Industry Looking For?
Preclinical Models e.g.
Muscle Models
Biomarkers e.g. Imaging
Preclinical &
Clinical CROs
Real World Evidence
& Health Economics
Outcomes
Top Reasons to Partner
Gain unparalleled brand visibility: Reach 70+ senior leaders from top pharmaceutical and biotech companies, including Novartis, Regeneron and Syntis Bio
Showcase your innovative solutions: Position your company as a thought leader in obesity treatment and highlight the offerings to a Summit dedicated to decision-makers
Bespoke valuable relationships: Connect with potential collaborators, investors, and key opinion leaders within the obesity treatment landscape
Gain valuable market insights: Stay ahead of the curve by gaining access to the latest scientific advancements, regulatory updates, and emerging trends in obesity treatment
Who Will You Meet?
